Last reviewed · How we verify

Treatment with tirzapatide

University Medical Centre Ljubljana · FDA-approved active Small molecule

Tirzapatide is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces glucagon levels in response to elevated blood glucose.

Tirzapatide is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces glucagon levels in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight.

At a glance

Generic nameTreatment with tirzapatide
SponsorUniversity Medical Centre Ljubljana
Drug classGLP-1/GIP receptor agonist
TargetGLP-1R, GIPR
ModalitySmall molecule
Therapeutic areaEndocrinology/Diabetes
PhaseFDA-approved

Mechanism of action

Tirzapatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, leading to glucose-dependent insulin secretion, suppression of glucagon, and delayed gastric emptying. This dual mechanism results in improved glycemic control and weight loss in patients with type 2 diabetes. The GIP component provides additional metabolic benefits beyond traditional GLP-1 monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: